Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
May 05, 2025 09:33 ET | Source: Research and Markets

Oncology Liquid Biopsy Market Outlook 2025-2035: Early Detection and Personalized Medicine Propel Widespread Adoption of Liquid Biopsy Technologies

Dublin, May 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Liquid Biopsy Market - A Global and Regional Analysis: Focus on Offering, Indication, Clinical Application, End User and Country-Level Analysis...
April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.
April 25, 2025 16:15 ET | Source: Castle Biosciences, Inc.

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025.
April 25, 2025 07:43 ET | Source: Junshi Biosciences

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Toripalimab was approved by the NMPA as the first-line treatment for unresectable or metastatic melanoma, the 12th indication in the Chinese mainland.
April 21, 2025 08:45 ET | Source: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.
April 03, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making.
April 02, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
March 21, 2025 16:30 ET | Source: Immuneering Corporation

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Corporation Announces Grant of Inducement Award

Next Page keyboard_arrow_right